Vaccination strategies in follicular lymphoma
- First Online:
- 85 Downloads
Follicular lymphoma is one of the most immuneresponsive cancers. The clonal tumor immunoglobulin expressed on the surface of malignant B cells, termed idiotype, has been used as a tumor-specific antigen in therapeutic vaccination strategies for follicular lymphoma and other B-cell malignancies. A number of phase 1 and phase 2 clinical trials have established the safety and immunogenicity of idiotype vaccine in follicular lymphoma. Three randomized, double-blind, controlled phase 3 clinical trials have recently been completed to definitively evaluate the clinical benefit of idiotype vaccine in follicular lymphoma. This review focuses on the results of these idiotype vaccine trials and discusses poten tial strategies to enhance the efficacy of vaccines in the future.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106, 3725–3732.PubMedCrossRefGoogle Scholar
- 19.Santos C, Stern L, Katz L, et al.: BiovaxID vaccine therapy of follicular lymphoma in first remission: long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial [abstract 2441]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 2441.Google Scholar
- 23.Koc O, Redfern C, Wiernik P, et al.: Extended follow-up and analysis with central radiological review of patients receiving FavId [abstract 772]. Blood (ASH Annual Meeting Abstracts) 2005, 106:772.Google Scholar
- 24.Schuster SJ, Neelapu SS, Gause BL, et al.: Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results [abstract 2]. J Clin Oncol 2009, 27(Suppl):18s.Google Scholar
- 25.Levy R, Robertson M, Ganjoo K, et al.: Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non Hodgkin’s lymphoma (fNHL) [abstract LB-204]. In Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 12–16, 2008.Google Scholar
- 26.Freedman A, Neelapu SS, Nichols C, et al.: Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009, 27:3036–3043.PubMedCrossRefGoogle Scholar
- 36.Foglietta M, Delgado D, Nattamai D, et al.: CD4+Foxp3+ regulatory T cells persist in high numbers in peripheral blood after induction of clinical remission with standard chemotherapy and suppress tumor-specific effector T cells in patients with follicular lymphoma [abstract 3778]. Blood (ASH Annual Meeting Abstracts) 2008, 112:309.Google Scholar
- 39.Nattamai D, Neelapu SS: PD-1 expression is markedly upregulated on intratumoral CD4+ and CD8+ T cells in follicular lymphoma and is associated with T-cell exhaustion [abstract 2749]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 2749.Google Scholar